Sell-side equity research analysts have handed shares of Gilead Sciences, Inc. (NASDAQ:GILD) a short term price target of $100.785. Based on the 14 firms providing predictions, this is the mean, or consensus number according to Zacks Research. Investment analysts will project a certain price level that they anticipate the stock price reaching. Analysts may have different opinions on where a stock is headed. They may use different techniques to project a future price level.
Using technical analysis, analysts and traders may use previous support and resistance levels to help determine a realistic target. Price target estimates may vary drastically from analyst to analyst. The highest current target price estimate provided by analysts polled by Zacks Research stands at $118. The lowest target price estimate from these same analysts is $88.
Zacks research also gives calculated recommendations from sell-side analysts that cover company shares. These recommendations land on a simplified scale provided by Zacks Research. Using data provided from various analysts, shares of Gilead Sciences, Inc. (NASDAQ:GILD) are presently listed with an ABR of 1.81. This number is using a recommendation scale where the ratings range from a 1 to a 5. Following this scale, a 1 would signify a Strong Buy while a 5 would represent a Strong Sell.
We can also take a look at some company earnings per share or EPS information. Earnings per share is the segment of profit for a company that is allocated to every outstanding share of a company’s common stock. Earnings per share numbers can serve as an indicator for the profitability of a certain company. EPS is broadly thought to be one of the most important factors when evaluating the price of a share. A Zacks consensus currently shows Street analysts projecting the company to post per share earnings of $2.52. For the period ending 2016-09-30, Gilead Sciences, Inc. (NASDAQ:GILD) reported actual EPS of $2.7. This number was $-0.04 away from analyst predictions, providing a surprise factor of -1.46%. The company is expected to next release earnings on or around 2017-02-07.
The data in this report is in part provided by Zacks Research and Yahoo Finance. The author does not have, nor plans to take any position in Gilead Sciences, Inc. shares within the next 14 days. Readers should not consider this as a recommendation to buy or sell company stock. This piece is for informational purposes only. Potentialy investors should always conduct full research before making investment decisions.